Sarah Romano's departure as Chief Financial Officer of Vicarious Surgical Inc. was reported, effective July 22, 2026; the filing names no successor. As of November 6, 2026, Vicarious Surgical Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 24, 2026 to July 21, 2026, naming 1 departure (Form 8-K, June 24, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Vicarious Surgical Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Vicarious Surgical Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-24 to 2026-07-21. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Vicarious Surgical Inc. files it.
Also on the record for Vicarious Surgical Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 15, 2025 | Form D, private offering | $11.73M sold | Form D page | Source |
Selling to them or working with them? See who runs Vicarious Surgical Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Vicarious Surgical Inc. and the records around it.
Vicarious Surgical Inc. elsewhere on the record
- Form D filing Oct 2025
- Who owns it
Watch Vicarious Surgical Inc.
Get an email when Vicarious Surgical Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vicarious Surgical Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Vicarious Surgical Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vicarious Surgical Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-21 | Reported | not named in the filing | 8-K, 2026-07-21 | ||
| 2026-06-24 | Out | Chief Financial Officer | 2026-07-22 | 8-K, 2026-06-24 |
Who leads Vicarious Surgical Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Sarah Romano, departure reported, effective 2026-07-22 (filed 2026-06-24). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Vicarious Surgical Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Vicarious Surgical Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Vicarious Surgical Inc.Every change, in the filing's words
Reported
On July 21, 2026, each of the members of the Board (Joseph Doherty, Stephen From, Adam Sachs, Sammy Khalifa, David Ho, Victoria Carr-Brendel, and Fuad Ahmad), each provided notice of his or her decision to resign from the Board and all committees thereof, effective upon the filing of the Form 15 with the Securities and Exchange Commission (the "SEC").
- The resignations were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- On July 21, 2026, in connection with the Assignment, the Company terminated the employment of each of Stephen From, the Company's Chief Executive Officer, Adam Sachs, the Company's President, Sammy Khalifa, the Company's Chief Technology Officer, and Dr. Barry Greene, the Company's Chief Medical Officer, effective as of the close of business on July 21, 2026.
- Messrs. From, Sachs and Khalifa are entitled to severance benefits pursuant to employment agreements.
- The Company entered into an employment agreement with Mr. From pursuant to which Mr. From is entitled to receive a severance payment equal to $672,699.
- In addition, his outstanding equity awards with time-based vesting will vest in full.
- The Company entered into an employment agreement with Mr. Sachs pursuant to which Mr. Sachs is entitled to receive a severance payment equal to $779,190.
- In addition, his outstanding equity awards with time-based vesting will vest in full.
- The Company entered into an employment agreement with Mr. Khalifa pursuant to which Mr. Khalifa is entitled to receive a severance payment equal to $611,261.
- In addition, his outstanding equity awards with time-based vesting will vest in full.
Departing: Sarah Romano, Chief Financial Officer, effective 2026-07-22
On June 24, 2026, Sarah Romano notified the Board of Directors of her resignation as Chief Financial Officer of the Company, effective July 22, 2026, or such later date as may be mutually agreed upon by the Company and Ms. Romano.
- Ms. Romano's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- Ms. Romano will continue to serve as Chief Financial Officer through the effective date of her resignation.
Tools for this story
Each opens in a new tab, filled in for Vicarious Surgical Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.